In conclusion, available data indicate the perspective of an effective strategy for treatment of ARDS and COVID-19 by direct and selective stimulation of the Protective Arm of RAS by AT2R- or MasR-specific, peptidase-resistant agonists. Here, MAS1L is linked to COVID-19.